XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
Rhea-AI Summary
XTL Biopharmaceuticals (Nasdaq:XTLB) received a Nasdaq staff delist determination dated February 25, 2026, citing the company as a public shell after its subsidiary The Social Proxy entered liquidation on February 22, 2026. The company intends to request a hearing to stay suspension and appeal the delisting.
Nasdaq also cited noncompliance with the $2,500,000 stockholders’ equity requirement and the $1.00 minimum bid price (noncompliance notified December 20, 2025). If no timely hearing request is filed by March 4, 2026, ADSs may be suspended March 6, 2026.
Positive
- Hearing request can stay suspension pending Panel decision
- Company can appeal Nasdaq delisting by March 4, 2026
Negative
- Nasdaq staff determined company is a public shell (Feb 25, 2026)
- Subsidiary The Social Proxy ordered liquidation by court on Feb 22, 2026
- Noncompliance with $2,500,000 stockholders’ equity requirement (notified Jan 20, 2026)
- ADS bid price noncompliance under $1.00 (notified Dec 20, 2025); suspension possible Mar 6, 2026
News Market Reaction – XTLB
In the Mar 2 session, XTLB gained 0.25%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | Financing/compliance plan | Positive | +1.7% | Update on NeuroNOS deal and up to US$2.0M private placement to address equity. |
| Jan 23 | Equity deficiency notice | Negative | -10.1% | Nasdaq notice of stockholders’ equity deficit versus $2,500,000 listing requirement. |
| Jan 13 | NeuroNOS acquisition | Positive | +56.7% | Agreement to acquire 85% of NeuroNOS with cash, shares, and milestones. |
| Dec 24 | Bid price deficiency | Negative | -5.7% | Nasdaq notice that 30‑day bid fell below $1.00 minimum under Rule 5550(a)(2). |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Nasdaq‑related notices and capital plans have typically led to price moves that align with the tone of the news, with sharper declines on clearly negative compliance updates.
Over the past few months, XTLB has been dominated by listing‑compliance and restructuring headlines. A Dec 24, 2025 notice on minimum bid price and a Jan 23, 2026 equity‑deficiency notice both saw negative price reactions. In contrast, the Jan 13, 2026 NeuroNOS acquisition announcement produced a strong positive move of 56.66%. A Jan 29, 2026 update on efforts to close that deal and raise up to US$2.0 million had a modestly positive reaction. Today’s staff delisting determination extends this ongoing Nasdaq risk theme.
Key Terms
public shell financial
form 25-nse regulatory
insolvency proceedings regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated February 25, 2026, notifying the Company of the Staff’s belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a “public shell”, and that continued listing of the Company’s American Depositary Shares (“ADSs”) is no longer warranted. The Company intends to request a hearing (the “Hearing”) to appeal the delisting process before a Nasdaq Hearings Panel (the “Panel”). A Hearing request will stay the suspension of the ADSs and delisting pending the Panel’s decision.
The Letter stated that the Staff believes the Company no longer has an operating business, citing the Company’s prior public disclosure that its wholly owned subsidiary, The Social Proxy, had filed a formal application with the competent Israeli court for the commencement of insolvency proceedings and that on February 22, 2026, the court ordered The Social Proxy's liquidation and the appointment of a trustee for the insolvency proceedings. The Staff noted that the Company’s purported shell status could lead to the ADSs being subject to market abuses and other violative conduct and that purchasers of the Company’s securities do not know what the operating business of the Company will be in the future.
Additionally, and as previously disclosed by the Company, on January 20, 2026 the Staff notified the Company that it did not comply with the minimum
Unless the Company requests the Hearing by March 4, 2026, trading of the Company’s ADSs will be suspended from The Nasdaq Capital Market at the opening of business on March 6, 2026, and will subsequently be removed from listing and registration when Nasdaq files a Form 25-NSE with the SEC. A timely Hearing request will stay the suspension of the ADSs and delisting pending the Panel’s decision. There can be no assurance that the Panel will grant the Company’s request for continued listing.
About XTL Biopharmaceuticals Ltd.
XTL is an IP Portfolio company that holds
XTL trades on the Nasdaq Capital Market (NASDAQ: XTLB) and Tel Aviv Stock Exchange (TASE: XTLB.TA).
Cautionary Note Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this communication that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to (i) whether to the Company will be able to receive sub-licensing fees relating to its Hcdr1 intellectual property, (ii) the Company’s ability to successfully manage and integrate The Social Proxy and any other joint ventures, acquisitions of businesses, solutions or technologies; (iii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (iv) the ability to attract and retain qualified employees and key personnel; (v) adverse effects of increased competition on the Company’s future business; (vi) the Company’s ability to protect its intellectual property; (vii) the Company’s ability to successfully consummate the acquisition of
For further information, please contact:
Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972 3 611 6666
Email: info@xtlbio.com
www.xtlbio.com
